Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Heparin Crisis Spurs Changes In FDA Emergency Response Policies

This article was originally published in The Tan Sheet

Executive Summary

Internal and external evaluations of FDA's handling of the heparin contamination crisis of early 2008 have led to changes in the agency's emergency response strategy and a new policy on emergency collaborations with outside experts.

You may also be interested in...

Accelerated Approval: How The Aduhelm Probes Will, And Won’t, Impact The Debate

Even as the US FDA can expect to be put through the ringer with the congressional and HHS Inspector General probes, the process could have some upsides for the agency, according to former officials who have been through such scrutiny.

Barton Attracts Support In Uphill Bid For Energy and Commerce Chair

Rep. Joe Barton pushes to regain the Energy and Commerce Committee chair against the long odds of fellow Republicans appointing him to the post that wields significant influence over FDA and the OTC drug and nutritional product industries.

Heparin Fallout Likely To Impact Supplement Ingredient Testing Exemptions

The discovery of adulterated ingredients in imported prescription drugs will likely cause increased scrutiny of supply chain operations for other segments across the food and drug industries


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts